Generation of T cell responses targeting the reactive metabolite of halothane in mice

Toxicology Letters

Volumn 194, Issue 3, 2010, Pages 79-85

  You, Qiang ^a   Cheng, Linling ^a   Ju, Cynthia ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Anti CD40 antibody; CpG DNA; Drug; LPS; PolyI:C; TLR agonist

Indexed keywords

ACETIC ACID DERIVATIVE; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; HALOTHANE; LIVER PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; SERUM ALBUMIN; TOLL LIKE RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HEPATITIS; LIVER INJURY; METABOLITE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD40; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; FEMALE; HALOTHANE; MICE; MICE, INBRED STRAINS; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; TRIFLUOROACETIC ACID;

ANIMALIA; MURINAE; MUS;

EID: 77950865023     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.02.009     Document Type: Article

References (42)

1. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., Vasilakos J.P., Noelle R.J., Kedl R.M. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 2004, 199:775-784.
2. Akira S. Mammalian Toll-like receptors. Curr. Opin. Immunol. 2003, 15:5-11.
3. Benjamin S.B., Goodman Z.D., Ishak K.G., Zimmerman H.J., Irey N.S. The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology 1985, 5:1163-1171.
4. Bullock T.N., Yagita H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J. Immunol. 2005, 174:710-717.
5. Busch D.H., Pamer E.G. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 1999, 189:701-710.
6. Butz E., Bevan M.J. Dynamics of the CD8+ T cell response during acute LCMV infection. Adv. Exp. Med. Biol. 1998, 452:111-122.
7. Chen M., Gandolfi J. Characterization of the humoral immune response and hepatotoxicity after multiple halothane exposures in guinea pigs. Drug Metab. Rev. 1997, 29:103-122.
8. Cheng L., Stewart B.J., You Q., Petersen D.R., Ware J.A., Piccotti J.R., Kawabata T.T., Ju C. Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo. Mol. Pharmacol. 2008, 73:1769-1775.
9. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283:666-668.
10. Donker A.J., Venuto R.C., Vladutiu A.O., Brentjens J.R., Andres G.A. Effects of prolonged administration of d-penicillamine or captopril in various strains of rats. Brown Norway rats treated with d-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation. Clin. Immunol. Immunopathol. 1984, 30:142-155.
11. Fritz R.B., Chou C.H., McFarlin D.E. Relapsing murine experimental allergic encephalomyelitis induced by myelin basic protein. J. Immunol. 1983, 130:1024-1026.
12. Goldberger R.F. Trifluoroacetylation of [epsilon]-amino groups. Methods in Enzymology Enzyme Structure 1967, 317-322. Academic Press. H.W. Hirs (Ed.).
13. Goldberger R.F., Anfinsen C.B. The reversible masking of amino groups in ribonuclease and its possible usefulness in the synthesis of the protein. Biochemistry 1962, 1:401-405.
14. Heit A., Huster K.M., Schmitz F., Schiemann M., Busch D.H., Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J. Immunol. 2004, 172:1501-1507.
15. Hendriks J., Gravestein L.A., Tesselaar K., van Lier R.A., Schumacher T.N., Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 2000, 1:433-440.
16. Kenna J.G., Satoh H., Christ D.D., Pohl L.R. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 1988, 245:1103-1109.
17. Lavergne S.N., Trepanier L.A. Anti-platelet antibodies in a natural animal model of sulphonamide-associated thrombocytopaenia. Platelets 2007, 18:595-604.
18. Lore K., Betts M.R., Brenchley J.M., Kuruppu J., Khojasteh S., Perfetto S., Roederer M., Seder R.A., Koup R.A. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 2003, 171:4320-4328.
19. Masson M.J., Uetrecht J.P. Tolerance induced by low dose d-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem. Res. Toxicol. 2004, 17:82-94.
20. Mathieu A., Dipadua D., Kahan B.D., Galdabini J.J., Mills J. Correlation between specific immunity to a metabolite of halothane and hepatic lesions after multiple exposures. Anesth. Analg. 1975, 54:332-339.
21. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6:769-776.
22. Neuberger J., Kenna J.G. Halothane hepatitis: a model of immune mediated drug hepatotoxicity. Clin. Sci. (Lond.) 1987, 72:263-270.
23. Neuberger J.M., Kenna J.G., Williams R. Halothane hepatitis: attempt to develop an animal model. Int. J. Immunopharmacol. 1987, 9:123-131.
24. Pasare C., Medzhitov R. Toll-like receptors and acquired immunity. Semin. Immunol. 2004, 16:23-26.
25. Pohl L.R. Drug-induced allergic hepatitis. Semin. Liver Dis. 1990, 10:305-315.
26. Pohl L.R., Kenna J.G., Satoh H., Christ D., Martin J.L. Neoantigens associated with halothane hepatitis. Drug Metab. Rev. 1989, 20:203-217.
27. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 2004, 199:227-250.
28. Ray D.C., Drummond G.B. Halothane hepatitis. Br. J. Anaesth. 1991, 67:84-99.
29. Reves J.G., McCracken L.E. Failure to induce hepatic pathology in animals sensitized to a halothane metabolite and subsequently challenged with halothane. Anesth. Analg. 1976, 55:235-242.
30. Rhee E.G., Mendez S., Shah J.A., Wu C.Y., Kirman J.R., Turon T.N., Davey D.F., Davis H., Klinman D.M., Coler R.N., Sacks D.L., Seder R.A. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J. Exp. Med. 2002, 195:1565-1573.
31. Satoh H., Martin B.M., Schulick A.H., Christ D.D., Kenna J.G., Pohl L.R. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:322-326.
32. Shenton J.M., Teranishi M., Abu-Asab M.S., Yager J.A., Uetrecht J.P. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 2003, 16:1078-1089.
33. Taraban V.Y., Rowley T.F., Al Shamkhani A. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J. Immunol. 2004, 173:6542-6546.
34. Trepanier L.A. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J. Vet. Pharmacol. Ther. 2004, 27:129-138.
35. Tscharke D.C., Karupiah G., Zhou J., Palmore T., Irvine K.R., Haeryfar S.M., Williams S., Sidney J., Sette A., Bennink J.R., Yewdell J.W. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 2005, 201:95-104.
36. Vergani D., Mieli-Vergani G., Alberti A., Neuberger J., Eddleston A.L., Davis M., Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 1980, 303:66-71.
37. Waldhauser L., Uetrecht J. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Toxicology 1996, 114:155-162.
38. Walton B., Simpson B.R., Strunin L., Doniach D., Perrin J., Appleyard A.J. Unexplained hepatitis following halothane. Br. Med. J. 1976, 1:1171-1176.
39. Welters M.J., Bijker M.S., van den Eeden S.J., Franken K.L., Melief C.J., Offringa R., van der Burg S.H. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 2007, 25:1379-1389.
40. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., Kedl R.M., Mattapallil J.J., Weiss W.R., Roederer M., Seder R.A. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 2006, 203:1249-1258.
41. Wright R., Eade O.E., Chisholm M., Hawksley M., Lloyd B., Moles T.M., Edwards J.C., GArdner M.J. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet 1975, 1:817-820.
42. You Q., Cheng L., Reilly T.P., Wegmann D., Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006, 44:1421-1431.